Form 8-K - Current report:
SEC Accession No. 0001213900-25-063294
Filing Date
2025-07-11
Accepted
2025-07-11 16:30:30
Documents
13
Period of Report
2025-07-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea0248712-8k425_denali.htm   iXBRL 8-K 30436
  Complete submission text file 0001213900-25-063294.txt   249704

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE dnquf-20250711.xsd EX-101.SCH 4170
3 XBRL DEFINITION FILE dnquf-20250711_def.xml EX-101.DEF 27304
4 XBRL LABEL FILE dnquf-20250711_lab.xml EX-101.LAB 37896
5 XBRL PRESENTATION FILE dnquf-20250711_pre.xml EX-101.PRE 25924
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0248712-8k425_denali_htm.xml XML 7474
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 251119325
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)